Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=76 Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Lymphoma, Hodgkin Disease · Lymphoma · Hodgkin Disease
Primary: Progression-free Survival (PFS) — 89.7; 50 percentage of participants
N/A N=41 Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Hodgkin Lymphoma, Adult
Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants
Phase 2 N=58 Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
Classic Hodgkin Lymphoma · Lugano Classification Stage III Hodgkin Lymphoma AJCC v8 · Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
Primary: Event-free Survival (EFS) Rate — 17; 20 Participants
Phase 2 N=39 Rituximab in Treating Patients With Hodgkin's Lymphoma
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Phase 2 N=50 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Lymphoma
Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses
Phase 3 N=854 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Lymphoma
Primary: Failure-free Survival at 5 Years — 0.74; 0.71 Proportion of patients — p=0.32
Phase 2 N=80 Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
Phase 3 N=166 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma · Stage III Childhood Hodgkin Lymphoma · Stage IV Childhood Hodgkin Lymphoma
Primary: Second-event-free Survival — 0.91 Probability of survival
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 3 N=287 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Childhood Favorable Prognosis Hodgkin Lymphoma · Childhood Lymphocyte Depletion Hodgkin Lymphoma · Childhood Mixed Cellularity Hodgkin Lymphoma
Primary: Event Free Survival Without Receiving Radiation Therapy (EFSnoRT). — 0.49 Probability of survival
Phase 2 N=7 Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Hodgkin Disease · Hodgkin's Lymphoma · Lymphoma
Primary: Dose-limiting Toxicity of Gemcitabine Due to Non-hematologic Toxicity — 0; 3 participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=82 Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants
Phase 2 N=101 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Lymphoma
Primary: Progression-free Survival at 36 Months — 93.1; 89.7 percentage of participants — p=0.9669
Phase 2 N=96 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…
Phase 2 N=50 Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Primary: PART A: Number of Participants Who Complete of 2 Cycles of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) — 30 Participants
Phase 2 N=348 Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL) · Primary Mediastinal Large B-cell Lymphoma · Burkitt Lymphoma
Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants
Phase 2 N=118 Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
Phase 3 N=1,734 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma · Childhood Mixed Cellularity Classical Hodgkin Lymphoma · Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival
Phase 2 N=371 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Lymphoma · Nonneoplastic Condition
Primary: Percentage of HIV-negative Patients With 2-year Progression-free Survival (PFS) Treated With 2 Initial Cycles of Adriamycin, Bleomycin, Vnblastine, and Dacarbazine…
Phase 3 N=1,334 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Modified Progression-free Survival (mPFS) Per Independent Review Facility (IRF) — NA; NA months — p=0.035
Phase 2 N=49 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Complete Remission Rate After Chemotherapy — 38 Participants
Phase 2 N=24 Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients
Phase 2 N=41 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
AIDS-Related Hodgkin Lymphoma · Ann Arbor Stage II Hodgkin Lymphoma · Ann Arbor Stage IIA Hodgkin Lymphoma
Primary: Maximal Tolerated Dose of Brentuximab Vedotin (Phase I) — 1.2 mg/kg
Phase 4 N=60 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 50 percentage of participants
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients